1997
Long-term Perspective on the Prevalent-Cohort Biases in Studies of Human Immunodeficiency Virus Progression
Alcabes P, Pezzotti P, Phillips A, Rezza G, Vlahov D. Long-term Perspective on the Prevalent-Cohort Biases in Studies of Human Immunodeficiency Virus Progression. American Journal Of Epidemiology 1997, 146: 543-551. PMID: 9326431, DOI: 10.1093/oxfordjournals.aje.a009312.Peer-Reviewed Original ResearchConceptsPSP cohortRelative riskSeroincident cohortHIV infectionPrevalent cohortAIDS riskAcquired immunodeficiency syndrome (AIDS) diagnosisHuman immunodeficiency virus (HIV) infectionDisease Control case definitionHuman immunodeficiency virus (HIV) progressionImmunodeficiency syndrome diagnosisImmunodeficiency virus infectionPrevalent HIV infectionProportional hazards regressionAmbulatory care clinicsRate of progressionStudies of cohortsItalian National RegistryAIDS-free subjectsObserved relative riskSeroconversion datesHIV seroconversionCare clinicsHazards regressionNational registry
1996
An International Collaborative Study of the Effects of Coinfection with Human T-Lymphotropic Virus Type II on Human Immunodeficiency Virus Type 1 Disease Progression in Injection Drug Users
Hershow R, Galai N, Fukuda K, Graber J, Vlahov D, Rezza G, Klein R, Jarlais D, Vitek C, Khabbaz R, Freels S, Zuckerman R, Pezzotti P, Kaplan J. An International Collaborative Study of the Effects of Coinfection with Human T-Lymphotropic Virus Type II on Human Immunodeficiency Virus Type 1 Disease Progression in Injection Drug Users. The Journal Of Infectious Diseases 1996, 174: 309-317. PMID: 8699060, DOI: 10.1093/infdis/174.2.309.Peer-Reviewed Original ResearchConceptsInjection drug usersCD4 cell percentCell percentHuman immunodeficiency virus type 1 (HIV-1) disease progressionHuman immunodeficiency virus type 1 (HIV-1) infectionDrug usersInfected injection drug usersVirus type 1 infectionHuman T-lymphotropic virus type IIHIV seroconversion datesHTLV-II infectionType 1 infectionProportional hazards modelEffect of coinfectionSeroconversion datesCohort studyHIV infectionHTLV infectionDisease progressionAIDS mortalityHTLV-IIHazards modelRate of declineInternational collaborative studyWestern blot